5 results
AACE/ACE 2018 Glycemic Control Algorithm

#AACE #2018 #Glycemic #Diabetes #DM2 #Control #Medication #Algorithm #Endocrinology #PrimaryCare #Management
AACE/ACE 2018 Glycemic ... #AACE #2018 #Glycemic ... #Diabetes #DM2 ... #Control #Medication ... #Algorithm #Endocrinology
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... #medications #table ... #comparison #management ... #endocrinology ... #dm2
Pathophysiology of Diabetic Ketoacidosis (DKA) and Hyperglycemic Hyperosmolar Syndrome (HHS)
Absolute Insulin deficit:
 - Type I DM:
Ketoacidosis (DKA ... deficit: - Type I DM ... produced - Type II DM ... pathophysiology #comparison ... #endocrinology
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
mL/minute/1.73 m2 ... diabetic ketoacidosis ... (DKA) • Canagliflozin ... Pharmacology #Summary #DM2 ... #diabetes #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Type 2 Inpatient Medication ... #Mellitus #DM2 ... #Inpatient #Medications ... #pharmacology #comparison ... #table #endocrinology